Archive for the ‘Gene Therapy Research’ Category

The Bible - Homeland - Part 1
Joshua conquers Jericho; Delilah betrays Samson as the Israelites battle the Philistines; Samuel anoints David king, a move that could throw the nation into ...

By: FHEFoxTVProductions

View original post here:
The Bible - Homeland - Part 1 - Video

Patriotism

By: Eric Bottelberghe

Read more from the original source:
Patriotism - Video

Obama #39;s Reptilian Secret Sevice Spotted AIPAC Conference 3 Angles (HD)
WATCH IN 720p !!!! Apparently one of Obama #39;s Secret Service Agent spooks shapeshifted into some weird humanoid during his speech at 2012 AIPAC Zionist Confer...

By: 4ReptilianResistance

Read the original:
Obama's Reptilian Secret Sevice Spotted AIPAC Conference 3 Angles (HD) - Video

New 2014 Subaru XV Crosstreck Hybrid
Read more here: http://www.carscoops.com/2013/03/subaru-to-reveal-new-2014-xv-crosstrek.html.

By: Carscoop

Here is the original post:
New 2014 Subaru XV Crosstreck Hybrid - Video

Virginia Tech

Virginia Tech researchers used a gene disruption technique to change the eye color of a mosquito, a critical step toward new strategies for disrupting the transmission of diseases such as dengue fever. The eye colors of these mosquitoes are varied because of cell-to-cell variability in the degree of gene editing.

By Alan Boyle, Science Editor, NBC News

Scientists at Virginia Tech have disrupted the genes that control eye color in mosquitoes, using a genetic-engineering technique that could also disrupt the transmission of diseases such as dengue fever.

The technique relies on two specially designed proteins that belong to a class known as transcription activator-like effector nucleases, or TALENs. The technique can target DNA at a specific site in an organism's genetic code, so precisely and efficiently that the journal Science has called the molecules "genomic cruise missiles."

Virginia Tech entomologist Zach Adelman prefers a different analogy. "They're basically a very, very fine-tuned pair of scissors," he told NBC News.

TALENs have been used to edit the genomes of animal and human cell cultures, but Adelman said the approach he and his colleagues used on the mosquito genome was different. Rather than trying to modify the function of a gene, the researchers aimed to disable a gene by snipping away at it. In the journal PLOS ONE, they describe how they targeted a gene whose protein product is essential for the production of eye pigment in Aedes aegypti, the mosquito species linked to the transmission of dengue fever.

Genetically engineered TALEN proteins were injected into the germ cells of mosquito embryos early in their development, with the intention of disrupting the coding for eye pigmentation that would be passed down to the next generation. When the targeted mosquitoes gave birth to baby bugs, a large percentage of them had light-colored eyes instead of the typical black eyes. The lack of pigment served as confirmation that the genetic code was wiped out.

The next step is to identify the genetic mechanisms in mosquitoes that play a role in virus transmission. When the right targets are found, the researchers will try to design a different set of molecular scissors to disrupt that genetic code.

Adelman said he's been working on molecular strategies to fight mosquito-borne diseases for a dozen years, and began the TALEN-based project just last May.

See the article here:
Disease-fighters disrupt mosquito's genes with molecular 'cruise missiles'

Virginia Tech

Virginia Tech researchers used a gene disruption technique to change the eye color of a mosquito, a critical step toward new strategies for disrupting the transmission of diseases such as dengue fever. The eye colors of these mosquitoes are varied because of cell-to-cell variability in the degree of gene editing.

By Alan Boyle, Science Editor, NBC News

Scientists at Virginia Tech have disrupted the genes that control eye color in mosquitoes, using a genetic-engineering technique that could also disrupt the transmission of diseases such as dengue fever.

The technique relies on two specially designed proteins that belong to a class known as transcription activator-like effector nucleases, or TALENs. The technique can target DNA at a specific site in an organism's genetic code, so precisely and efficiently that the journal Science has called the molecules "genomic cruise missiles."

Virginia Tech entomologist Zach Adelman prefers a different analogy. "They're basically a very, very fine-tuned pair of scissors," he told NBC News.

TALENs have been used to edit the genomes of animal and human cell cultures, but Adelman said the approach he and his colleagues used on the mosquito genome was different. Rather than trying to modify the function of a gene, the researchers aimed to disable a gene by snipping away at it. In the journal PLOS ONE, they describe how they targeted a gene whose protein product is essential for the production of eye pigment in Aedes aegypti, the mosquito species linked to the transmission of dengue fever.

Genetically engineered TALEN proteins were injected into the germ cells of mosquito embryos early in their development, with the intention of disrupting the coding for eye pigmentation that would be passed down to the next generation. When the targeted mosquitoes gave birth to baby bugs, a large percentage of them had light-colored eyes instead of the typical black eyes. The lack of pigment served as confirmation that the genetic code was wiped out.

The next step is to identify the genetic mechanisms in mosquitoes that play a role in virus transmission. When the right targets are found, the researchers will try to design a different set of molecular scissors to disrupt that genetic code.

Adelman said he's been working on molecular strategies to fight mosquito-borne diseases for a dozen years, and began the TALEN-based project just last May.

Read the original:
Disease-fighters disrupt mosquito's genes with molecular scissors

DUBLIN, March 21, 2013 /PRNewswire/ --

Nearly two out of three people in four major European countries have no awareness of personalised medicine - despite the fact that this evolving discipline has vast implications for Europe's healthcare issues and Europeans' personal health. These statistics presented today at the European Alliance for Personalised Medicine (EAPM) conference taking place in Dublin, in association with the Irish EU Presidency, were part of the PACE Cancer Perception Index that studied knowledge and attitudes about cancer treatment and care, the healthcare system and patient involvement. PACE, a Lilly Oncology initiative, stands for Patient Access to Cancer care Excellence.

The EAPM Conference on Innovation and Patient Access to Personalised Medicine brought together researchers, patients, healthcare professionals, payers, regulators, policymakers and industry to evaluate the potential and the development of personalised medicine in light of the European economic crisis.[i]

Irish Minister of Health Dr. James Reilly stressed the potential of personalised medicine "to provide solutions that are better tailored to the individual patient than traditional 'one size fits all' medicinal products."[ii]

"Personalised medicine is a promising concept," said Tonio Borg, European Union (EU) Commissioner for Health and Consumers. "As patients are divided into groups based on their individual, biological, genetic and genomic characteristics, medical interventions are tailored to those patients' needs."

"Hence, this new approach can help reduce the risk of undesirable adverse reactions and at the same time, make medicines more effective," said Mr. Borg. "And it also yields a maximum return on healthcare investment - a valuable argument for decision makers, in times of austerity."[iii]

Public Supports Personalised Medicine

A highlight of the conference was a work group that discussed the importance of informed, engaged and empowered patients where personalised medicine is concerned. Central to the discussion were the results of the PACE Cancer Perception Index: A Six-Nation, Public Opinion Survey of Cancer Knowledge and Attitudes.

"The PACE Cancer Perception Index devoted a considerable amount of time to the subject of personalised medicine, and what we found was both surprising and promising," said Sue Mahony, Ph.D., president, Lilly Oncology.

"While only one-third of respondents were aware of personalised medicine, the majority were supportive once the concept was introduced," Dr. Mahony said. "They not only recognised its benefits for them and society, but they expressed a willingness to help by being tested for personalised medicine, and by sharing their medical information."

Read the original post:
Global Survey Underscores Importance of Patient Education and Engagement in Personalised Medicine

SANTA CLARA, Calif.--(BUSINESS WIRE)--

Affymetrix, Inc. (AFFX) today announced that it has signed a contract with UK Biobank to genotype 500,000 DNA samples donated by UK residents as part of a prospective epidemiological study of complex diseases that are of great relevance to public health. Affymetrix Axiom Genotyping Solution will be used to generate billions of high-quality genotypes which will provide UK Biobank and the research community with valuable insight to genetic factors underlying human diseases for improved prevention, diagnosis, and treatment of conditions such as heart disease, cancer, and diabetes.

Professor Rory Collins, UK Biobank CEO and Principal Investigator said: UK Biobank is pleased to join forces with Affymetrix for this next phase of the UK Biobank project. The two organizations will work closely together to ensure that world class data are provided quickly and securely to help scientists working on the causes of a wide range of life-threatening and disabling diseases. I urge health scientists everywhere to think carefully about how this resource could be used to help their research, and to register with UK Biobank. I am also very grateful to the half a million participants whose generosity and vision for the future has allowedthis resource to grow.

We are honored to partner with UK Biobank on this mission critical research initiative, said Dr. Frank Witney, President and CEO of Affymetrix. Earlier this year, we outlined our strategy to broaden our reach into the translational medicine, molecular diagnostics, and applied markets as part of our long-term transformation plan. This partnership reflects our efforts to strengthen our position in the growing translational medicine market and our commitment to work with visionary organizations such as the UK Biobank to produce the next generation of biological information that will improve healthcare.

Large scale genotyping studies such as the one undertaken by UK Biobank demand a flexible and scalable genomics analysis technology that produces a large amount of high quality data quickly, consistently, and cost-effectively. The unmatched flexibility, array reproducibility, and advanced design capabilities were key factors in UK Biobank adopting the Axiom Genotyping Solution. These platform capabilities have become increasingly important for genotyping studies in both the human and agbio markets as requirements shift away from very high-density, standardized designs toward customized high-fidelity arrays. We are very proud that our Axiom Genotyping Solution has been chosen for this incredibly important project, said Dr. Andy Last, EVP and General Manager of Genetic and Clinical Applications at Affymetrix.

Affymetrix expects to begin delivering data for the study towards the end of 2013. Affymetrix does not expect revenue from this contract to have a material impact in 2013, as it will start to recognize revenue in the latter part of this year, with the majority of the revenue expected to be recognized in 2014.

About UK Biobank:

UK Biobank is a major national health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses including cancer, heart diseases, stroke,diabetes, arthritis, osteoporosis, eye disorders,depressionand forms of dementia.UK Biobank recruited500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop particular diseases and others do not.

About Affymetrix

Affymetrix technologies are used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes. More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing our technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit http://www.affymetrix.com.

Read more here:
Affymetrix Signs Contract With UK Biobank to Genotype 500,000 UK Individuals in the Largest Ever Study of Genetic and ...

THE BOY WHO LIVED (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Want some gear? US Store: http://seananners.spreadshirt.com EU Store: http://seananners.spreadshirt....

By: SeaNanners

Here is the original post:
THE BOY WHO LIVED (The Hidden) - Video

"I Feel Like A Colon" with the Divine Ms Butt Meddler
Man! I feel like a colon! Why? The best thing about being a survivor Is the prerogative to show a little bun Women who are survivors of early onset ovarian o...

By: ButtMeddler

Read this article:
"I Feel Like A Colon" with the Divine Ms Butt Meddler - Video

Super Women Elite Desired Outcome Hangout - Jenn Jarecki Karen Flaherty

By: Jennifer Jarecki

Go here to read the rest:
Super Women Elite Desired Outcome Hangout - Jenn Jarecki

LOOK UP! (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Want some gear? US Store: http://seananners.spreadshirt.com EU Store: http://seananners.spreadshirt....

By: SeaNanners

See the original post here:
LOOK UP! (The Hidden) - Video

Why do we see illusions? - Mark Changizi
View full lesson: http://ed.ted.com/lessons/why-do-we-see-illusions-mark-changizi Why can #39;t our extremely complex eyes render simple optical illusions? Surpr...

By: TEDEducation

Continued here:
Why do we see illusions? - Mark Changizi - Video

Bad Genetics
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

Read the original:
Bad Genetics - Video

Back Workout With Mooji
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

View post:
Back Workout With Mooji - Video

How farming planted seeds for the Internet - Patricia Russac
View full lesson: http://ed.ted.com/lessons/how-farming-planted-seeds-for-the-internet-patricia-russac What does farming have to do with invention and innova...

By: TEDEducation

Continued here:
How farming planted seeds for the Internet - Patricia Russac - Video

Squats Necessary to Gain Muscle?
Thanks for the support! Please LIKE and COMMENT if you enjoy! #9675; Top 5 Bodybuilding Snacks: http://youtu.be/s0CLtvWk3dc #9675; Six Pack Abs Workout: http://youtu.b...

By: MichaelKoryFitness

See original here:
Squats Necessary to Gain Muscle? - Video

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU) announced today that it will host a conference call and Webcast on Thursday, March 28, 2013 at 4:30 p.m. (EST) to discuss the Companys fourth quarter and 2012 year end results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.s Website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

See more here:
Interleukin Genetics , Inc. Announces Conference Call to Discuss Fourth Quarter 2012 Results

PHOENIX--(BUSINESS WIRE)--

Good Start Genetics, Inc.,an innovative molecular diagnostics company which has developed the new gold standard in carrier screening, presented clinical data at this weeks annual meeting of the American College of Medical Genetics and Genomics (ACMG). These data were generated using its unique, next-generation sequencing (NGS) based carrier screening platform in the IVF setting.

In the first of two abstracts presented at ACMG, entitled Carrier Screening of 4,200 IVF Patients Utilizing Next Generation DNA Sequencing Detects Common, Rare and Otherwise Undetectable Mutations Across Several Diseases, the authors report the detection of numerous rare and novel pathogenic (i.e., disease-causing) mutations among 14 diseases in a clinical setting. The authors conclude that without NGS, these carriers would have been missed, putting the IVF couples at increased risk of having a child with one of these genetic disorders.

In the second abstract presented, entitled Next Generation DNA Sequencing Detects Rare and Novel Mutations Across Several Diseases, the authors describe the identification of 50 pathogenic alleles across ten diseases among over 3,300 patient samples screened. In this study, 34% of the mutations identified using Good Starts screening tests would have been missed had traditional tests been used.

These results clearly demonstrate that NGS can detect far more disease-causing mutations than can older screening technologies currently in use in the IVF setting, said Don Hardison, president and CEO of Good Start Genetics. Were very pleased to be able to offer this cutting edge technology to IVF centers across the country, and even more pleased that we are detecting carriers that would have otherwise been missed.

Since its national launch in April 2012, Good Start Genetics high-complexity, CLIA- and CAP-accredited laboratory has processed tens of thousands of test orders. The GoodStart Select carrier screening service detects common pathogenic (i.e., disease-causing) mutations in carriers across all 23 diseases recommended for testing by major medical societies, as well as rare pathogenic mutations that would go undetected by laboratories using older, traditional genotyping-based technologies. For example, most traditional genotyping-based technologies detect about 100 pathogenic mutations for cystic fibrosis (CF), while GoodStart Select detects 550 pathogenic mutations.

About Good Start Genetics, Inc.

Good Start Genetics is setting the new gold standard in carrier screening by making testing for the most comprehensive set of known and novel disease-causing mutations accessible for routine clinical practice. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable and affordable tests for all disorders recommended for genetic testing by ACOG and ACMG. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results, and no longer have to compromise accuracy for price. For more information, visit http://www.goodstartgenetics.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130321006005/en/

Read more:
Good Start Genetics Reports Clinical Data at the Annual Meeting of the American College of Medical Genetics and ...

Pain Control Clinic scottsdale az | 480-448-1152
http://www.arizonaklaserneuropathycenter.com/ Pain Control Clinic scottsdale az 480-448-1152 Laser Therapy is non-invasive, drug free and painless and there ...

By: PainControlClinic

Read more:
Pain Control Clinic scottsdale az | 480-448-1152 - Video

A clinical trial using a patient's own immune system to produce remissions in adults with acute leukemia could be a major breakthrough in the fight against all different kinds of cancer.

The new study, published Wednesday in the journal Science Translational Medicine, took five patients with untreatable cancer, and using their own immune systems, injected genetic material into the patient's white cells to turn them into cancer fighters. The modified white cells then went out in the body and destroyed all the cancer cells, causing the patients to go into remission, according to the study.

"Cancer cells are similar enough to your normal cells that the T-cells cannot recognize it," Dr. Richard M. Stone, Program Director of the Adult Leukemia Program at the Dana-Farber Cancer Institute, told ABC News. "By injecting genes into these cells, you're educating the immune system to recognize the cancer."

This study only reviewed patients with acute lymphoblastic leukemia. While 80 to 90 percent of children with ALL can be cured with conventional therapy, adult ALL is genetically different and only enjoys a cure rate of roughly 40 percent.

Of the five patients, four had bone marrow transplants after receiving the new treatment. The other patient suffered medical problems that made a transplant impossible, relapsed and died shortly thereafter.

One of the patients, known in the study as Patient 5, is David Aponte, 58, a sound man at ABC News.

Last summer, Aponte underwent a physically and emotionally taxing regimen of chemotherapy. However, while still undergoing treatment, doctors discovered that the disease was back. With few options left, he decided to join the new T-cell study.

Doctors took millions of Aponte's disease-fighting white blood cells, and used a retrovirus to change those cells into targeted cancer fighters. The treatment can cause side effects, including what is known as a "cytokine storm," in which the engineered T-cells become activated, releasing all kinds of proteins that can make the patient ill. For Aponte, this meant a drop in blood pressure, a fever that spiked to 105 degrees and a coma that lasted eight days.

"Down the road if this continues to be developed, one could imagine therapies that would modulate the side effects, slowing down the anti-tumor response," explained Dr. Stone.

Aponte's treatment was successful, and he became one of the patients who successfully went into remission. When he awoke from the coma, not one cancer cell could be found. His leukemia was gone.

More here:
Gene Therapy Could Treat Cancer, Study Finds

A clinical trial using a patient's own immune system to produce remissions in adults with acute leukemia could be a major breakthrough in the fight against all different kinds of cancer.

The new study, published Wednesday in the journal Science Translational Medicine, took five patients with untreatable cancer, and using their own immune systems, injected genetic material into the patient's white cells to turn them into cancer fighters. The modified white cells then went out in the body and destroyed all the cancer cells, causing the patients to go into remission, according to the study.

"Cancer cells are similar enough to your normal cells that the T-cells cannot recognize it," Dr. Richard M. Stone, Program Director of the Adult Leukemia Program at the Dana-Farber Cancer Institute, told ABC News. "By injecting genes into these cells, you're educating the immune system to recognize the cancer."

This study only reviewed patients with acute lymphoblastic leukemia. While 80 to 90 percent of children with ALL can be cured with conventional therapy, adult ALL is genetically different and only enjoys a cure rate of roughly 40 percent.

Of the five patients, four had bone marrow transplants after receiving the new treatment. The other patient suffered medical problems that made a transplant impossible, relapsed and died shortly thereafter.

One of the patients, known in the study as Patient 5, is David Aponte, 58, a sound man at ABC News.

Sciepro/Science Photo Library/Corbis

Last summer, Aponte underwent a physically and emotionally taxing regimen of chemotherapy. However, while still undergoing treatment, doctors discovered that the disease was back. With few options left, he decided to join the new T-cell study.

Doctors took millions of Aponte's disease-fighting white blood cells, and used a retrovirus to change those cells into targeted cancer fighters. The treatment can cause side effects, including what is known as a "cytokine storm," in which the engineered T-cells become activated, releasing all kinds of proteins that can make the patient ill. For Aponte, this meant a drop in blood pressure, a fever that spiked to 105 degrees and a coma that lasted eight days.

"Down the road if this continues to be developed, one could imagine therapies that would modulate the side effects, slowing down the anti-tumor response," explained Dr. Stone.

See original here:
Gene Therapy Could Treat Cancer

Topics: babies, dna, ivf

THE possibility that babies could be born with the DNA of three different people is a step closer, after a consultation showed that most Britons would be happy to see the law changed to allow a radical form of gene therapy.

The IVF therapy would help women in danger of passing on mitochondrial disease to their babies - a potentially fatal metabolic disorder.

An exhaustive survey of public attitudes to the replacement of an affected mother's mitochondria - the tiny "power packs" of cells - with those from an egg donor has found widespread support for the technique.

>>More Lifestyle News

"We've found that there is broad support for permitting mitochondria replacement to give families at risk of mitochondrial disease the chance of having a healthy child," said Professor Lisa Jardine, the chair of the Human Fertilisation and Embryology Authority (HFEA).

"Although some people have concerns about the safety of these techniques, we found that they trust the experts and the regulator to know when it is appropriate to make them available."

But David King, director of Human Genetics Alert, criticised the HFEA for ignoring the potential risks associated with the technique, which has had only limited testing on laboratory animals and is not medically practised anywhere in the world.

"These techniques go far beyond anything existing in both invasiveness to the embryo and complexity, so it's not surprising they pose serious health risks to the child - risks that the HFEA refuses properly to address," Dr King said.

Mitochondrial replacement involves fusing the egg-cell nucleus of the affected mother with an egg cell from an unaffected donor.

Excerpt from:
Public supports gene therapy on IVF embryos

Dr Alok Sharma Stem Cell Therapy Treatment for Stroke
Dr Alok Sharma Stem Cell Therapy Treatment for Stroke before and after compareson After Stem Cell Therapy 1) Can walk almost 50-60 steps at a time without ex...

By: neurogenbsi

Read more here:
Dr Alok Sharma Stem Cell Therapy Treatment for Stroke - Video

The Department of Health (DOH) has restricted hospitals and other facilities from using genetically-altered cells and tissues of human in carrying out stem-cell therapy and treatments in the country. Health secretary Enrique Ona added that their department also prohibits the use of umbilical cord, fat-derived human stem cells, and live animal stem cells for the conduct of the procedure locally.

Related story: Foundation seeks to help people on the verge of suicide On Wednesday, DOH released Administrative Order (AO) 2013-0012 which seeks to ensure the safety of people who want to undergo human stem cell and cell-based therapies.

The AO also prohibits for human treatment and research the creation of human embryos and their derivatives, the use of aborted human fetal stem cells and their derivatives, and plant parts labeled as stem cells, the order stated. Ona hopes AO will make effective and ethical stem cell modalities and practices that will be at par with emerging international and global standards on the very complex nature of this therapy.

Also read: Genetically modified crops threaten organic agriculture He explained the AO also hopes to prevent the introduction, transmission, and spread of communicable diseases by ensuring a minimum quality of service and staff qualification rendered by hospitals and other health facilities capable of utilizing human stem cell preparations and cell-based therapies. These guidelines will classify which stem cell preparations and therapies will be registered and allowed with certain restrictions, Ona said in a statement. Preparations that will be allowed include those with adult human stem cells, human umbilical cord stem cells, and human organ-specific cells, he noted.

Related story: Fresh food make up most of Pinoys' shopping basket, says study He explained that health facilities utilizing stem cell preparations and cell-based or cellular therapies will be mandated to comply with the guidelines set by DOHs Bioethics Advisory Board. The Borad, Ona notes, will ensure that ethical and professional standards are upheld and that contentious scientific, ethical and legal issues are addressed. He said charges and complaints shall be addressed to the DOH Bureau of Health Facilities & Services and the Philippine Food and Drug Agency. Stem cell therapy and treatments are medical procedures where doctors replace malignant cells with healthier cells in an effort to cure or address ailments like cancer. Some facilities also use the procedure for cosmetic purposes, targeting components of the skin like collagen to make patients look younger and healthy.

More here:
DOH restricts hospitals amid stem- cell therapy craze